Azathioprine: Current status and future considerations

International Journal of Dermatology

Volumn 42, Issue 5, 2003, Pages 335-341

  El Azhary, Rokea A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALLOPURINOL; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BENZOIC ACID DERIVATIVE; CORTICOSTEROID; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; THIOPURINE METHYLTRANSFERASE; WARFARIN; XANTHINE OXIDASE;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME INDUCTION; EOSINOPHILIA; ERYTHROCYTE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HUMAN; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER TOXICITY; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MELANOMA; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREATITIS; PHENOTYPE; PREGNANCY TEST; RHABDOMYOLYSIS; SKIN CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; AZATHIOPRINE; DERMATOLOGIC AGENTS; DRUG INTERACTIONS; ERYTHROCYTES; HUMANS; METHYLTRANSFERASES; MOLECULAR STRUCTURE; POLYMORPHISM, GENETIC; THIOGUANINE;

EID: 0037529212     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2003.01823.x     Document Type: Conference Paper

References (69)

1. Calne RY. The initial study of the immunosuppressive effects of 6-mercaptopurine and azathioprine in organ transplantation and a few words on cyclosporin A. World J Surg 1982; 6: 637-640.
2. Calne RY, Alexandre GP, Murray JE. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs. Ann NY Acad Sci 1962; 99: 743-761.
3. Schwartz RS. Immunosuppression: Back to the future. World J Surg 2000; 24: 783-786.
4. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 1994; 343: 1188-1190.
5. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567-572.
6. Bergan S. Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements. Biodrugs 1997; 8: 446-456.
7. Zimm S, Collins JM, Riccardi R, et al. Variable bioavailability of oral mercaptopurine: Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983; 308: 1005-1009.
8. Van Os EC, Zins BJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996; 39: 63-68.
9. Sauer H, Hantke U, Wilmanns W. Azathioprine lymphocytotoxicity: Potentially lethal damage by its imidazole derivatives. Arzneimittelforschung 1988; 38: 820-824.
10. Van Loon JA, Weinshilboum RM. Thiopurine methyltransferase biochemical genetics: Human lymphocyte activity. Biochem Genet 1982; 20: 637-658.
11. Woodson LC, Dunnette JH, Weinshilboum RM. Pharmacogenetics of human thiopurine methyltransferase: Kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther 1982; 222: 174-181.
12. Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6: 279-290.
13. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: The thiopurine S-methyltransferase paradigm. Pharm Res 1999; 16: 342-349.
14. Remy CN. Metabolism of thiopyrimidines and thiopurines. S-methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem 1963; 238: 1078-1084.
15. Glauser TA, Kerremans AL, Weinshilboum RM. Human hepatic microsomal thiol methyltransferase: Assay conditions, biochemical properties, and correlation studies. Drug Metab Dispos 1992; 20: 247-255.
16. Deininger M, Szumlanski CL, Otterness DM, et al. Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol 1994; 48: 2135-2138.
17. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
18. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 1151.
19. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993; 69: 577-579.
20. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999; 105: 696-700.
21. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662.
22. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: Getting personal. Am J Hum Genet 1998; 63: 11-16.
23. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-2301.
24. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 60-73.
25. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999; 8: 371-376.
26. Ameyaw MM, Collie-Duguid ES, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999; 8: 367-370.
27. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129: 716-718.
28. Spire-Vayron De La Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998; 125: 879-887.
29. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999; 9: 37-42.
30. McLeod HL, Relling MV, Liu Q, et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995; 85: 1897-1902.
31. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-197.
32. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995; 32: 114-116.
33. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-713.
34. Leipold G, Schutz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondyloarthritis. Arthritis Rheum 1997; 40: 1896-1898.
35. Soria-Royer C, Legendre C, Mircheva J, et al. Thiopurine-methyl-transferase activity to assess azathioprine myelotoxicity in renal transplant recipients. Lancet 1993; 341: 1593-1594.
36. Pike MG, Franklin CL, Mays DC, et al. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B: Biomed Sci Appl 2001; 757: 1-9.
37. Bergan S, Rugstad HE, Bentdal O, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation 1998; 66: 334-339.
38. Mircheva J, Legendre C, Soria-Royer C, et al. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation 1995; 60: 639-642.
39. Thervet E, Anglicheau D, Toledano N, et al. Clinical consequences of the polymorphism of azathioprine metabolism. Transplant Proc 2000; 32: 2780.
40. Meggitt SJ, Reynolds NJ. Azathioprine for atopic dermatitis. Clin Exp Dermatol 2001; 26: 369-375.
41. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85: 323-333.
42. Zietkiewicz E, Yotova V, Jarnik M, et al. Nuclear DNA diversity in worldwide distributed human populations. Gene 1997; 205: 161-171.
43. Saarikoski S, Seppala M. Immunosuppression during pregnancy: Transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115: 1100-1106.
44. Ostensen M. Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation. Am J Reprod Immunol 1992; 28: 148-152.
45. Flores F, Kerdel FA. Other novel immunosuppressants. Dermatol Clin 2000; 18: 475-483, ix.
46. Scerri L. Azathioprine in dermatological practice: An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol 1999; 455: 343-348.
47. Buckley DA, Baldwin P, Rogers S. The use of azathioprine in severe adult atopic eczema. J Eur Acad Dermatol Venereol 1998; 11: 137-140.
48. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris: A long-term follow-up. J Am Acad Dermatol 1987; 16: 527-533.
49. Dave VK, Vickers CF. Azathioprine in the treatment of muco-cutaneous pemphigoid. Br J Dermatol 1974; 90: 183-186.
50. Norris PG, Hawk JL. Successful treatment of severe polymorphous light eruption with azathioprine. Arch Dermatol 1989; 125: 1377-1379.
51. Al Mazyad AS. Polyarteritis nodosa in Arab children in Saudi Arabia. Clin Rheumatol 1999; 18: 196-200.
52. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine: An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991; 127: 515-522.
53. Thorkelsen H, Berdal P. Wegener's granulomatosis, immunosuppressive therapy. Acta Otolaryngol 1976; 82: 208-211.
54. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: Effects on long-term prognosis. Arthritis Rheum 1997; 40: 769-774.
55. Jones RR. Azathioprine therapy in the management of persistent erythema multiforme. Br J Dermatol 1981; 105: 465-467.
56. Lear JT, English JS. Erosive and generalized lichen planus responsive to azathioprine. Clin Exp Dermatol 1996; 21: 56-57.
57. Primka EJ III, Camisa C. Psoriasis and bullous pemphigoid treated with azathioprine. J Am Acad Dermatol 1998; 39: 121-123.
58. Verma KK, Sirka CS, Khaitan BK. Generalized severe lichen planus treated with azathioprine. Acta Derm Venereol 1999; 79: 493.
59. Berkovitch M, Matsui D, Zipursky A, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics. Med Pediatr Oncol 1996; 26: 85-89.
60. Compton MR, Crosby DL. Rhabdomyolysis associated with azathioprine hypersensitivity syndrome. Arch Dermatol 1996; 132: 1254-1255.
61. Jones JJ, Ashworth J. Azathioprine-induced shock in dermatology patients. J Am Acad Dermatol 1993; 29: 795-796.
62. Pandhi RK, Gupta LK, Girdhar M. Azathioprine-induced drug fever. Int J Dermatol 1994; 33: 198.
63. Fields CL, Robinson JW, Roy TM, et al. Hypersensitivity reaction to azathioprine. South Med J 1998; 91: 471-474.
64. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995; 133: 460-462.
65. Whisnant JK, Pelkey J. Rheumatoid arthritis: Treatment with azathioprine (IMURAN (R)): Clinical side-effects and laboratory abnormalities. Ann Rheum Dis 1982; 41 (Suppl. 1): 44-47.
66. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39: 456-459.
67. Lennard L. Clinical implications of thiopurine methyltransferase: Optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998; 20: 527-531.
68. Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996; 49: 393-396.
69. Rivier G, Khamashta MA, Hughes GR. Warfarin and azathioprine: A drug interaction does exist. Am J Med 1993; 95: 342.